4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 49,652 | N/A | N/A | N/A |
| Receivables | 978 | N/A | N/A | N/A |
| TOTAL | $52,508 | $N/A | $N/A | $N/A |
| Non-Current Assets | ||||
| PPE Net | 5,049 | N/A | N/A | N/A |
| Other Non-Current Assets | 677 | 0 | 0 | 0 |
| TOTAL | $5,726 | $N/A | $N/A | $N/A |
| Total Assets | $58,234 | $N/A | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,744 | 0 | 0 | 0 |
| Accrued Expenses | 5,347 | N/A | N/A | N/A |
| TOTAL | $12,955 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | ||||
| Deferred Revenues | 5,864 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 104,646 | 0 | 0 | 0 |
| TOTAL | $118,249 | $N/A | $N/A | $N/A |
| Total Liabilities | $131,204 | $N/A | $N/A | $N/A |
| Shareholders' Equity | ||||
| Common Shares | 1 | N/A | N/A | N/A |
| Retained earnings | -79,025 | N/A | N/A | N/A |
| TOTAL | $-72,970 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $58,234 | $0 | $0 | $0 |